Journal article
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
Cancer, Vol.126(1), pp.105-111
01/01/2020
DOI: 10.1002/cncr.32515
PMID: 31509242
Abstract
Background
This single‐arm, multicenter, phase 2 study evaluated the safety and antitumor activity of pazopanib in patients with unresectable or metastatic conventional chondrosarcoma.
Methods
Eligible patients had conventional chondrosarcoma of any grade with measurable tumors that were unresectable or metastatic. Patients with mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes and patients who received prior tyrosine kinase inhibitor therapy were excluded. Pazopanib at 800 mg once daily was administered for 28‐day cycles. Tumor responses were evaluated by local radiology assessments every 2 cycles. The primary endpoint was the disease control rate (DCR) at week 16 (4 cycles).
Results
Forty‐seven patients were enrolled. The DCR at 16 weeks was 43% (95% confidence interval [CI], 28%‐58%), which was superior to the null hypothesis rate of 30%, but the 2‐sided P value (exact test) was .09 (1‐sided P = .045). One patient had a partial response. The median overall survival was 17.6 months (95% CI, 11.3‐35.0 months), and the median progression‐free survival was 7.9 months (95% CI, 3.7‐12.6 months). Grade 3 or higher adverse events were infrequent; hypertension (26%) and elevated alanine aminotransferase (9%) were most common.
Conclusions
This study provides evidence of positive drug activity for pazopanib in conventional chondrosarcoma.
This single‐arm, multicenter, phase 2 study evaluates the safety and antitumor activity of pazopanib in patients with unresectable or metastatic conventional chondrosarcoma. This study provides evidence of positive drug activity for pazopanib in conventional chondrosarcoma.
Details
- Title: Subtitle
- Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
- Creators
- Warren Chow - City Of Hope National Medical CenterPaul Frankel - City Of Hope National Medical CenterChris Ruel - City Of Hope National Medical CenterDejka M. Araujo - The University of Texas MD Anderson Cancer CenterMohammed Milhem - University of IowaScott Okuno - Mayo ClinicLee Hartner - University of PennsylvaniaSamir Undevia - Edward HospitalArthur Staddon - University of Pennsylvania
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.126(1), pp.105-111
- DOI
- 10.1002/cncr.32515
- PMID
- 31509242
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Number of pages
- 7
- Grant note
- Novartis Pharmaceuticals Corporation
- Language
- English
- Date published
- 01/01/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359593502771
Metrics
4 Record Views